卵巢癌患者普遍基因评估:系统综述与荟萃分析
该系统综述与荟萃分析纳入35项研究,评估卵巢癌患者基因评估的利用率及干预效果。无干预时转诊遗传咨询和完成基因检测的合并率分别为39%和30%。主流化等临床医生主导的干预可提高检测率,黑种人及无保险者检测率较低。
要点
- 无干预时卵巢癌患者基因检测完成率仅30%,远低于普遍检测目标。
- 主流化遗传服务干预下基因评估率可达99%。
- 黑种人及无保险者基因检测率显著低于白种人及有保险者。
核心结论
- 卵巢癌患者基因检测报告率仍远低于普遍检测目标,主流化等干预可提高检测接受度,并需关注种族和保险状态差异。
研究设计与样本
- 系统综述与荟萃分析,检索关键电子数据库,纳入35项评估卵巢癌患者基因评估利用率的试验。
主要发现
- 无干预时转诊遗传咨询合并估计为39%[CI 27-53%],完成基因检测为30%[CI 19-44%]。
- 临床医生主导干预的基因评估率:主流化99%[CI 86-100%],远程医疗75%[CI 43-93%],诊所嵌入遗传咨询师76%[CI 32-95%],反射肿瘤体细胞遗传评估64%[CI 17-94%],普遍检测57%[CI 28-82%],转诊表格26%[CI 10-53%]。
- 黑种人vs白种人基因检测率26%[CI 17-38%] vs 40%[CI 25-57%],无保险vs有保险23%[CI 18-28%] vs 38%[CI 26-53%]。
临床怎么用
- 应优先采用主流化等临床医生主导的干预策略以提高卵巢癌患者基因检测率。
- 实施基因服务改进策略时需考虑种族和保险状态相关的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several professional organizations recommend universal genetic assessment for people with ovarian cancer as identifying pathogenic variants can affect treatment, prognosis, and all-cause mortality for patients and relatives. We sought to evaluate the literature on genetic assessment for women with ovarian cancer and determine if any interventions or patient characteristics drive utilization of services. METHODS: We searched key electronic databases to identify trials that evaluated genetic assessment for people with ovarian cancer. Trials with the primary aim to evaluate utilization of genetic assessment with or without interventions were included. Eligible trials were subjected to meta-analysis and the moderating influence of health interventions on rates of genetic assessment were examined. RESULTS: A total of 35 studies were included (19 report on utilization of genetic services without an intervention, 7 with an intervention, and 9 with both scenarios). Without an intervention, pooled estimates for referral to genetic counseling and completion of genetic testing were 39% [CI 27-53%] and 30% [CI 19-44%]. Clinician-facilitated interventions included: mainstreaming of genetic services (99% [CI 86-100%]), telemedicine (75% [CI 43-93%]), clinic-embedded genetic counselor (76% [CI 32-95%]), reflex tumor somatic genetic assessment (64% [CI 17-94%]), universal testing (57% [28-82%]), and referral forms (26% [CI 10-53%]). Random-effects pooled proportions demonstrated that Black vs. White race was associated with a lower rate of genetic testing (26%[CI 17-38%] vs. 40% [CI 25-57%]) as was being un-insured vs. insured (23% [CI 18-28%] vs. 38% [CI 26-53%]). CONCLUSIONS: Reported rates of genetic testing for people with ovarian cancer remain well below the goal of universal testing. Interventions such as mainstreaming can improve testing uptake. Strategies aimed at improving utilization of genetic services should consider existing disparities in race and insurance status.
引用
- Lin J, Sharaf RN, Saganty R, et al. Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecol Oncol. 2021. PMID: 34023131. doi:10.1016/j.ygyno.2021.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。